NEW YORK, Dec. 01, 2017 /PRNewswire/ --
In keeping with the commitment to dynamically provide members with timely
On Thursday, shares in Maryland headquartered Inovalon Holdings Inc. recorded a trading volume of 401,675 shares. The stock ended the session 0.63% higher at $15.90. The Company's shares have gained 17.34% over the previous three months and 54.37% on an YTD basis. The stock is trading 14.98% above its 200-day moving average. Moreover, shares of Inovalon, which provides cloud-based platforms empowering a data-driven transformation from volume-based to value-based models throughout the healthcare industry, have a Relative Strength Index (RSI) of 48.16.
On November 20th, 2017, Inovalon Holdings announced a collaboration with the University of Maryland's Center for Health Information and Decision Systems (CHIDS) as part of its expanding applications of machine learning and neural network solutions within the predictive analytic Components of the Inovalon ONE™ Platform. Through this engagement, CHIDS will join the Company's ongoing development initiative focused on Natural Language Processing, Machine Learning, and Deep Learning solutions utilized within the Inovalon ONE™ Platform. Get started with a complimentary subscription and access to the free report on INOV at: http://www.wallstequities.com/registration/?symbol=INOV
New York headquartered Medidata Solutions Inc.'s stock closed the day 2.55% higher at $66.64. A total volume of 829,519 shares was traded, which was above their three months average volume of 546,070 shares. The Company's shares have advanced 34.17% since the start of this year. The stock is trading 5.52% below its 200-day moving average. Additionally, shares of Medidata Solutions, which provides cloud-based solutions for life sciences worldwide, have an RSI of 38.95.
On November 13th, 2017, research firm Dougherty & Company upgraded the Company's stock rating from 'Neutral' to 'Buy', with a target price of $75 per share.
On November 15th, 2017, Medidata Solutions and ICON, a global provider of drug development solutions and services, announced a new collaboration to enhance the management of medical imaging during drug development research. ICON will expand its use of the Medidata Clinical Cloud® to include image management services for end-to-end digital control of the Healthcare industry's fastest-growing data source. Free research on MDSO can be accessed at: http://www.wallstequities.com/registration/?symbol=MDSO
Shares in Georgia headquartered Cotiviti Holdings Inc. recorded a trading volume of 461,622 shares, which was higher than their three months average volume of 384,840 shares. The stock ended yesterday's trading session 2.73% higher at $32.68. The Company's shares are trading below their 50-day moving average by 3.35%. Furthermore, shares of Cotiviti, which develops and sells analytics-driven payment accuracy solutions primarily for the healthcare sector, have an RSI of 51.26.
On November 16th, 2017, Cotiviti announced the appointment of R. Halsey Wise as an independent director of the Company, effective December 01st, 2017. Mr. Wise's appointment expands the Board to ten directors, and he will be a member of the Company's Compensation Committee. Visit WallStEquities.com now and sign up for the free research on COTV at: http://www.wallstequities.com/registration/?symbol=COTV
New York headquartered Teladoc Inc.'s stock finished Thursday's session 4.36% higher at $37.10. A total volume of 3.45 million shares was traded which was above their three months average volume of 1.08 million shares. The Company's shares have advanced 12.25% in the last one month, 10.58% over the previous three months, and 124.85% since the start of this year. The stock is trading above its 50-day and 200-day moving averages by 14.56% and 24.03%, respectively. Additionally, shares of Teladoc, which operates a telehealth platform that provides on-demand healthcare services to its members in the US, have an RSI of 66.20.
On November 21st, 2017, research firm Oppenheimer reiterated its 'Outperform' rating on the Company's stock with an increase of the target price from $40 a share to $45 a share.
On November 29th, 2017, Teladoc announced the pricing of the previously announced offering of shares of its common stock, which includes 3,454,000 shares offered by the Company and 830,000 shares offered by certain of its stockholders named in the preliminary prospectus supplement, at a price to the public of $35.00 per share. The offering is expected to close on or about December 04th, 2017, subject to customary closing conditions. The free technical report on TDOC is available at: http://www.wallstequities.com/registration/?symbol=TDOC
Wall St. Equities:
Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
WSE has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit https://wallstequities.com/legal-disclaimer/
CONTACTFor any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:Email: [email protected]Phone number: +21-32-044-483Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
View original content:http://www.prnewswire.com/news-releases/pre-market-technical-scan-on-healthcare-information-services-equities----inovalon-medidata-solutions-cotiviti-and-teladoc-300565013.html
SOURCE Wall St. Equities
Subscribe to our Free Newsletters!
Sarcoma, is a cancer that may arise from several soft-tissues or bone. Treatment in early stages is ...
A wonder drug, soda bicarb or baking soda can be used for skin, teeth, hair, kidneys and much more ...
Melasma, also called as chloasma, is a skin hyperpigmentation problem characterized by brown spots ...View All